Predictive value of the <scp>CLL</scp>‐<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemo‐immunotherapy as first‐line treatmentMassimo Gentile, Fortunato Morabito, Tait D. Shanafelt et al.|European Journal Of Haematology|2018Cited by 12
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor modelStefano Molica, Francesca Romana Mauro, Valerio Guarente et al.|American Journal of Hematology|2022Cited by 10
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximabMassimo Gentile, Fortunato Morabito, Tait D. Shanafelt et al.|Leukemia|2018Cited by 9
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Luca Laurenti, Idanna Innocenti et al.|Hematological Oncology|2023Cited by 2
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Lara Crucitti, Andrea Galitzia et al.|Haematologica|2025Cited by 2